Core Viewpoint - Annovis Bio, Inc. is hosting a live webcast to provide updates on its clinical trials for neurodegenerative diseases, specifically Alzheimer's disease and Parkinson's disease, while engaging with patients, caregivers, and families [1][2][3] Group 1: Webcast Details - The webcast will feature CEO Dr. Maria Maccecchini discussing the ongoing Phase 3 trial for Alzheimer's disease, plans for the Phase 3 trial for Parkinson's disease, and patient communication strategies [2] - A short presentation will highlight recent achievements, followed by a Q&A session where attendees can submit questions in advance [2] Group 2: Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, focusing on innovative therapies for neurodegenerative diseases by targeting multiple neurotoxic proteins to restore brain function [4] - The company emphasizes its commitment to transparency and patient engagement, aiming to address questions from current and prospective patients [3] Group 3: Investor Engagement - Investors and shareholders are encouraged to sign up for press releases and industry updates through the company's email alerts [5] - The updated investor website offers comprehensive access to company news, financial reports, and other key information [5]

Core Insights - Annovis Bio Inc. is a late-stage clinical drug platform company focused on developing therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease [1][4] - The CEO, Dr. Maria Maccecchini, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference, discussing the company's advancements and the pivotal Phase 3 trial for its drug, buntanetap [1][2] Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases like Alzheimer's and Parkinson's [4] - The company aims to develop innovative therapies that enhance patient outcomes and quality of life [4] Conference Details - The Oppenheimer's Annual Healthcare Life Sciences Conference is a significant event that gathers leading companies and investors in the healthcare and life sciences sectors [3] - The conference features presentations from industry executives, offering insights into current trends, innovations, and investment opportunities [3]

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD. "The launch of our highly anticipated AD study is a significant milestone in advancing bunta ...

Core Viewpoint - Annovis Bio Inc. has initiated a pivotal Phase 3 study for its drug candidate, buntanetap, aimed at treating early Alzheimer's disease, marking a significant step towards market approval and addressing the needs of millions of patients [1][2]. Study Details - The Phase 3 trial is a randomized, placebo-controlled, double-blind study designed to assess the safety and efficacy of a daily dose of buntanetap over 18 months, with a 6-month symptomatic assessment followed by a 12-month evaluation of potential disease-modifying effects [3]. - The study protocol received FDA approval based on positive results from previous trials, which indicated significant cognitive improvement in a subgroup of early AD patients without safety concerns [3]. Financial Aspects - The company recently completed a public offering of 5,250,000 units, generating gross proceeds of $21 million, which will fund the initial 6-month portion of the study, with additional capital expected from warrant exercises for the 12-month phase [4]. Participant Enrollment - Annovis plans to enroll over 750 participants across approximately 100 sites in the United States, with the first two sites already recruiting patients [7]. Drug Mechanism - Buntanetap is an orally available molecule that targets neurodegeneration by inhibiting neurotoxic protein aggregation, improving axonal transport, synaptic transmission, and reducing neuroinflammation, potentially reversing neurodegeneration and enhancing patients' quality of life [8]. Company Overview - Annovis Bio Inc. is focused on developing therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's disease, and is headquartered in Malvern, Pennsylvania [9].

MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4. ...

MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4.00 per share. The war ...

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it intends to offer to sell common stock and warrants in an underwritten public offering. All of the common stock and warrants are to be sold by the Company. ThinkEquity is acting as sole book-runn ...

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. This newly issued patent is based on buntanetap's ability to reduce neurotoxicity a ...

MALVERN, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025. In October 2024, the FDA granted clearance for Annovis to proceed with the pivota ...

LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce Annovis Bio’s (NYSE: ANVS) recent feature on Today’s Marketplace (TMP) as part of its commitment to amplifying industry leaders’ voices through targeted distribution channels. The full interview can be viewed at https://ibn.fm/m7gvX. This TMP episode highlights an exclusive interview with Dr. Mari ...